CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 10-K Report Annual Report
- 8-K Event Material agreement · Results of operations · New debt or obligation
- EFFECT Other Notice of Effectiveness
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 424B3 Offering Prospectus
- CORRESP Other Correspondence Between Filers and SEC Staff
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- UPLOAD Other SEC-generated Letter
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- S-3 Offering Registration Statement
- S-3 Offering Registration Statement
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market buy 10% owner bought 561,797 shares at $8.90 ($4,999,993)
- SC 13D/A Stake Beneficial Ownership Report
Page 7 of 14 · 268 filings